Pfizer · Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog
Source-backed profile assembled from linked signals and intelligence records.
Roche's promising Phase II data on enicepatide and petrelintide positions the company as a formidable player in the obesity treatment market. This advancement could significantly impact market dynamics, compelling competitors to reassess their strategies. Assessment grounded in 14 ranked evidence items (13 high-relevance).
Indication
Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog
Mechanism
No explicit mechanism overlap identified in available text.
Stage
Phase II
Sponsor
How this asset fits within the company's broader intelligence footprint.
Material intelligence activity detected across Diabetes, GLP-1, Oncology, Prostate Cancer, RET fusion-positive lung cancer. Highest priority: Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026 (Portfolio development). Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026 is an owned Pfizer portfolio development in Oncology · NSCLC. Competitive pressure: High. Portfolio impact: High. Evidence coverage: 71%.
FDA, EMA, PMDA, and other regulatory milestones from linked signals and precedents.
As retatrutide progresses through trials, its potential approval could set new standards for obesity treatments, influencing regulatory pathways for similar therapies.
View detailThe advancement of enicepatide and petrelintide into Phase III trials indicates a pathway towards regulatory approval, which could lead to new treatment options in a market with significant unmet needs.
View detailThe advancement of enicepatide and petrelintide through clinical trials suggests a pathway to regulatory approval, which could alter the competitive landscape for obesity treatments.
View detailAll intelligence signals linked to this asset.
Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.
Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.
In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs and significant reductions in knee osteoarthritis pain.
Verified competitive findings linked to this asset. Self-competition and invalid findings are excluded.
Potential competitive pressure
Potential competitive pressure
Potential competitive pressure
Potential competitive pressure
Source-backed references used to construct this page.
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
ClinicalTrials.gov
FDA document
View sourceEfficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: Multicenter, Double-blind, Randomized, Placebo-controlled Study
ClinicalTrials.gov
FDA document
View sourceA Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Ea
ClinicalTrials.gov
FDA document
View sourceThe Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Clinical Trial
ClinicalTrials.gov
FDA document
View sourceProspective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls.
ClinicalTrials.gov
FDA document
View sourceA Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
ClinicalTrials.gov
FDA document
View source12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMed
FDA document
View sourceFolate receptor-targeted PEGylated PLGA nanoparticles for the site-specific delivery of hesperidin in epithelial ovarian cancer.
PubMed
FDA document
View sourceSafety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMed
FDA document
View sourceTebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
PubMed
FDA document
View sourceEarly effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data.
PubMed
FDA document
View sourceBurden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMed
FDA document
View sourceRoche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide
Roche
FDA document
View sourceRoche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Roche
FDA document
View sourceRoche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide
Roche
FDA document
View sourceRoche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Roche
FDA document
View sourceLilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial
Lilly
FDA document
View sourceLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
Eli Lilly
FDA document
View sourcePfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management
Humanexa Signals
Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management
Pfizer
FDA document
View source